| Literature DB >> 35747592 |
Vasilios Theodoulidis1, Anastasia Prodromidou1, Emmanouil Stamatakis2, Nicholas Alexakis3, Alexandros Rodolakis1, Dimitrios Haidopoulos1.
Abstract
For the resection of diaphragmatic disease in patients with advanced ovarian cancer (OC), a plethora of ablative methods have been utilized. The present study aimed to present preliminary data on the use of J-Plasma in OC with diaphragmatic involvement via a retrospective review of patients who had diaphragmatic stripping with of J-Plasma® from January 2016 to September 2020. A total of 12 patients (median age, 65 years) were analyzed. Median operative time was 240 min while median estimated blood loss was 400 ml. Median operative time for diaphragmatic resection was 25 min. During a median follow-up of 12 months, two recurrences were noted while none of the patients died of the disease. Median disease free survival was 12 months. Overall, the preliminary outcomes of the present study indicated that J-Plasma could be safely used in diaphragmatic resection and it was associated with low rates of short-term morbidity. However, further studies are warranted to reach to safe conclusions.Entities:
Keywords: J-Plasma; cytoreduction; debulking surgery; diaphragmatic resection; epithelial ovarian cancer
Year: 2022 PMID: 35747592 PMCID: PMC9204212 DOI: 10.3892/mco.2022.2546
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450